Nebokitug Biosimilar Monoclonal Antibody (CCL24) for Research

Cat No.: GMP-Bios-INN-1291

Anti-CCL24/SCYA24/Ckb-6/MPIF-2/eotaxin-2 therapeutic antibody (Pre-made Nebokitug biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture,  assay development,  animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Nebokitug (development code CM-101) is a monoclonal antibody targeting CCL24. It is developed by Chemomab Therapeutics for hepatic fibrosis, NASH, and primary sclerosing cholangitis. It is in Phase II clinical development.

Order Information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
Catalog No. Package Price(In USD)
GMP-Bios-INN-1291-1mg 1mg 3090
GMP-Bios-INN-1291-10mg 10mg
GMP-Bios-INN-1291-100mg 100mg
GMP-Bios-INN-1291-xmg ≥100mg



Product Details

Products Name (INN Index) Pre-Made Nebokitug biosimilar, Whole mAb, Anti-CCL24/SCYA24/Ckb-6/MPIF-2/eotaxin-2 Antibody: Anti-CCL24/Eotaxin 2/C-C motif chemokine 24/CK-beta-6 therapeutic antibody
INN Name Nebokitug
Target CCL24/SCYA24/Ckb-6/MPIF-2/eotaxin-2
Format Whole mAb
Derivation Humanized
Species Reactivity Human
CH1+2+3 Isotype G1
VD LC Kappa
Highest_Clin_Trial (Jan '20) Phase-II
Est. Status Active
100% SI Structure None
99% SI Structure None
95-98% SI Structure None
Year Proposed 2024
Year Recommended na
Companies Chemomab Therapeutics
Conditions Approved na
Conditions Active Hepatic fibrosis;Non-alcoholic steatohepatitis;Primary sclerosing cholangitis
Conditions Discontinued na
Production na
Development Tech na